Description
Phase
Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.Inclusion and Exclusion Criteria
Please contact the trial administrator to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.
Sites
-
California
- University of Southern California, Los Angeles, California, 90033
- Harbor - University of California Los Angeles Medical Center, Torrance, California, 90503
- Stanford University, Stanford, California, 94305
-
Texas
- Baylor University Medical Center, Soltero Cardiovascular Research Center, Dallas, Texas, 75226
- University of Texas, Houston, Houston, Texas, 77030
-
Illinois
- Advocate Christ Medical Center, Oak Lawn, Illinois, 60453
-
Tennessee
- Vanderbilt University Medical Center, Nashville, Tennessee, 37212
- Erlanger Health System, Chattanooga, Tennessee, 37404
- Memorial Hospital, Chattanooga, Tennessee, 37404
-
Alabama
- University of Alabama-Birmingham, Birmingham, Alabama, 35294
-
Indiana
- Indiana Heart-St. Vincent Medical Group, Indianapolis, Indiana, 46290
- Indiana Ohio Heart, Fort Wayne, Indiana, 46804
-
Ohio
- Lindner Research Center-Christ Hospital, Cincinnati, Ohio, 45219
-
Michigan
- Cardiac and Vascular Research Center of Northern Michigan, Petoskey, Michigan, 49770
Powered by
SC CTSI